BDO Wealth Advisors LLC Invests $145,000 in Amgen Inc. (AMGN)
BDO Wealth Advisors LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 841 shares of the medical research company’s stock, valued at approximately $145,000.
Several other institutional investors also recently modified their holdings of the company. TrimTabs Asset Management LLC raised its position in Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the last quarter. American Beacon Advisors Inc. purchased a new stake in Amgen in the 1st quarter valued at $106,000. Nelson Roberts Investment Advisors LLC purchased a new stake in Amgen in the 1st quarter valued at $121,000. Grove Bank & Trust raised its position in Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 341 shares during the last quarter. Finally, Enterprise Financial Services Corp raised its position in Amgen by 18.0% in the 2nd quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 114 shares during the last quarter. Institutional investors and hedge funds own 78.20% of the company’s stock.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.
WARNING: “BDO Wealth Advisors LLC Invests $145,000 in Amgen Inc. (AMGN)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/13/bdo-wealth-advisors-llc-invests-145000-in-amgen-inc-amgn.html.
AMGN has been the subject of several research reports. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Monday, July 17th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a research report on Saturday, July 22nd. Cann restated a “buy” rating and set a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Deutsche Bank AG restated a “hold” rating and set a $174.00 price objective (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Thirteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $190.03.
Shares of Amgen Inc. (NASDAQ AMGN) opened at $172.35 on Monday. The stock has a market cap of $125,110.70, a P/E ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Amgen Inc. has a 12 month low of $138.83 and a 12 month high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 earnings per share. sell-side analysts forecast that Amgen Inc. will post 12.66 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.67%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is currently 41.63%.
Amgen announced that its board has initiated a share repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.